Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer.

Literature DB >> 26122284

Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer.

Katharina Kreymborg¹, Stefan Haak², Rajmohan Murali³, Joyce Wei⁴, Rebecca Waitz¹, Georg Gasteiger¹, Peter A Savage⁵, Marcel R M van den Brink⁶, James P Allison⁷.

Abstract

The costimulatory molecules B7-H3 and B7-H4 are overexpressed in a variety of human tumors and have been hypothesized as possible biomarkers and immunotherapeutic targets. Despite this potential, the predominating uncertainty about their functional implication in tumor-host interaction hampers their evaluation as a target for cancer therapy. By means of a highly physiologic, spontaneous tumor model in mice, we establish a causal link between B7-H3 and host tumor control and found B7-H4 to be redundant. ©2015 American Association for Cancer Research.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 26122284 PMCID： PMC5939565 DOI： 10.1158/2326-6066.CIR-15-0100

Source DB: PubMed Journal: Cancer Immunol Res ISSN： 2326-6066 Impact factor: 11.151

18 in total

1. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes.

Authors: Christina Tekle; Marit Kveine Nygren; Yih-Wen Chen; Indrejit Dybsjord; Jahn Marthin Nesland; Gunhild Mari Maelandsmo; Oystein Fodstad
Journal: Int J Cancer Date: 2011-08-08 Impact factor: 7.396

2. Improved survival with ipilimumab in patients with metastatic melanoma.

Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245

Review 3. Regulatory T cells in cancer immunotherapy.

Authors: Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal: Curr Opin Immunol Date: 2014-01-14 Impact factor: 7.486

4. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors: Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal: Nat Med Date: 2004-08-22 Impact factor: 53.440

5. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors: Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal: Cancer Res Date: 2013-04-22 Impact factor: 12.701

6. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains.

Authors: Peter Steinberger; Otto Majdic; Sophia V Derdak; Katharina Pfistershammer; Stefanie Kirchberger; Christoph Klauser; Gerhard Zlabinger; Winfried F Pickl; Johannes Stöckl; Walter Knapp
Journal: J Immunol Date: 2004-02-15 Impact factor: 5.422

Review 7. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

Authors: K S Peggs; S A Quezada; J P Allison
Journal: Clin Exp Immunol Date: 2009-02-18 Impact factor: 4.330

8. Prostate cancer in a transgenic mouse.

Authors: N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal: Proc Natl Acad Sci U S A Date: 1995-04-11 Impact factor: 11.205

9. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors: D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal: Proc Natl Acad Sci U S A Date: 1998-06-23 Impact factor: 11.205

10. Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells.

Authors: J Kraan; P van den Broek; C Verhoef; D J Grunhagen; W Taal; J W Gratama; S Sleijfer
Journal: Br J Cancer Date: 2014-06-03 Impact factor: 7.640

16 in total

Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer.

1. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes.

2. Improved survival with ipilimumab in patients with metastatic melanoma.

Review 3. Regulatory T cells in cancer immunotherapy.

4. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

5. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

6. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains.

Review 7. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

8. Prostate cancer in a transgenic mouse.

9. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

10. Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells.

1. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

2. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.

Review 3. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Review 4. Bone marrow chimeras-a vital tool in basic and translational research.

Review 5. Macrophages as regulators of tumour immunity and immunotherapy.

6. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.

Review 7. Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Review 8. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

9. Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists.

10. High expression of cluster of differentiation 276 indicates poor prognosis in glioma.